Hoerr; Ingmar

Patent Applications and Registrations

Patent applications and USPTO patent grants for Hoerr; Ingmar.The latest application filed is for "composition for treating lung cancer, particularly of non-small lung cancers (nsclc)".

Company Profile

13.22.72

Hoerr; Ingmar - Tubingen N/A DE
HOERR; Ingmar - Stuttgart DE
Hoerr; Ingmar - Tuebingen DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
RNA-coded antibody Grant 11,421,038 - Hoerr , et al. August 23, 2	2022-08-23
Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions Grant 11,369,691 - Von Der Mulbe , et al. June 28, 2	2022-06-28
Composition For Treating Lung Cancer, Particularly Of Non-small Lung Cancers (nsclc) App 20220096616 - BARNER; Marijke ; et al.	2022-03-31
Rna Encoding A Therapeutic Protein App 20220025369 - FOTIN-MLECZEK; Mariola ; et al.	2022-01-27
Injection Solution For Rna App 20210308238 - HOERR; Ingmar ; et al.	2021-10-07
Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions Grant 11,135,312 - Von Der Mulbe , et al. October 5, 2	2021-10-05
RNA encoding a therapeutic protein Grant 11,078,247 - Fotin-Mleczek , et al. August 3, 2	2021-08-03
NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT App 20200085942 - KRAMPS; Thomas ; et al.	2020-03-19
Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions Grant 10,568,972 - Von Der Mulbe , et al. Feb	2020-02-25
Rna Encoding An Antibody App 20200023076 - FOTIN-MLECZEK; Mariola ; et al.	2020-01-23
NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT App 20200016264 - HOERR; Ingmar ; et al.	2020-01-16
COMPOSITION FOR TREATING PROSTATE CANCER (PCa) App 20190365879 - PROBST; Jochen ; et al.	2019-12-05
Rna Encoding A Tumor Antigen App 20190343942 - FOTIN-MLECZEK; Mariola ; et al.	2019-11-14
Nucleic acid comprising G.sub.lX.sub.mG.sub.n as an immune-stimulating agent/adjuvant Grant 10,441,653 - Hoerr , et al. Oc	2019-10-15
Composition for treating prostate cancer (PCa) Grant 10,434,154 - Probst , et al. O	2019-10-08
Rna-coded Antibody App 20190284260 - HOERR; Ingmar ; et al.	2019-09-19
Rna Encoding A Therapeutic Protein App 20190241633 - FOTIN-MLECZEK; Mariola ; et al.	2019-08-08
PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS App 20190134222 - VON DER MULBE; Florian ; et al.	2019-05-09
Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions Grant 10,188,748 - Von Der Mulbe , et al. Ja	2019-01-29
Composition For Treating Lung Cancer, Particularly Of Non-small Lung Cancers (nsclc) App 20180256694 - Barner; Marijke ; et al.	2018-09-13
Injection Solution For Rna App 20180214523 - Hoerr; Ingmar ; et al.	2018-08-02
New Targets For Rna Therapeutics App 20180126003 - HOERR; Ingmar	2018-05-10
Immunostimulation By Chemically Modified Rna App 20170211068 - HOERR; Ingmar ; et al.	2017-07-27
Application of mRNA for use as a therapeutic against tumour diseases Grant 9,655,955 - Hoerr , et al. May 23, 2	2017-05-23
COMPOSITION FOR TREATING PROSTATE CANCER (PCa) App 20170000871 - PROBST; Jochen ; et al.	2017-01-05
Combination Therapy For Immunostimulation App 20170000870 - HOERR; Ingmar ; et al.	2017-01-05
PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS App 20160361438 - VON DER MULBE; Florian ; et al.	2016-12-15
Composition For Treating Lung Cancer, Particularly Of Non-small Lung Cancers (nsclc) App 20160346370 - BARNER; Marijke ; et al.	2016-12-01
Composition For Treating Lung Cancer, Particularly Of Non-small Lung Cancers (nsclc) App 20160317636 - BARNER; Marijke ; et al.	2016-11-03
COMPOSITION FOR TREATING PROSTATE CANCER (PCa) App 20160303210 - PROBST; Jochen ; et al.	2016-10-20
Application of mRNA for use as a therapeutic against tumour diseases Grant 9,463,228 - Hoerr , et al. October 11, 2	2016-10-11
Application of mRNA for use as a therapeutic against tumour diseases Grant 9,439,956 - Hoerr , et al. September 13, 2	2016-09-13
Application of mRNA for use as a therapeutic against tumour diseases Grant 9,433,670 - Hoerr , et al. September 6, 2	2016-09-06
Application of mRNA for use as a therapeutic against tumor diseases Grant 9,433,669 - Hoerr , et al. September 6, 2	2016-09-06
NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT App 20160250321 - KRAMPS; Thomas ; et al.	2016-09-01
Composition for treating prostate cancer (PCa) Grant 9,402,887 - Probst , et al. August 2, 2	2016-08-02
Rna-coded Antibody App 20160185840 - HOERR; Ingmar ; et al.	2016-06-30
Rna-coded Antibody App 20160166691 - HOERR; Ingmar ; et al.	2016-06-16
Rna-coded Antibody App 20160166690 - HOERR; Ingmar ; et al.	2016-06-16
Rna-coded Antibody App 20160168254 - HOERR; Ingmar ; et al.	2016-06-16
Rna-coded Antibody App 20160166692 - HOERR; Ingmar ; et al.	2016-06-16
Rna-coded Antibody App 20160152691 - HOERR; Ingmar ; et al.	2016-06-02
Rna-coded Antibody App 20160152706 - HOERR; Ingmar ; et al.	2016-06-02
Composition for treating lung cancer, particularly of non-small lung cancers (NSCLC) Grant 9,352,028 - Barner , et al. May 31, 2	2016-05-31
Rna-coded Antibody App 20160145346 - Hoerr; Ingmar ; et al.	2016-05-26
PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS App 20160136243 - Von Der Mulbe; Florian ; et al.	2016-05-19
PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS App 20160136247 - VON DER MULBE; Florian ; et al.	2016-05-19
PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS App 20160136263 - Von Der Mulbe; Florian ; et al.	2016-05-19
PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS App 20160136301 - VON DER MULBE; Florian ; et al.	2016-05-19
PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS App 20160136258 - Von Der Mulbe; Florian ; et al.	2016-05-19
PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS App 20160136259 - Von Der Mulbe; Florian ; et al.	2016-05-19
PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS App 20160129105 - VON DER MULBE; Florian ; et al.	2016-05-12
APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES App 20160095912 - HOERR; Ingmar ; et al.	2016-04-07
APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES App 20160095911 - HOERR; Ingmar ; et al.	2016-04-07
APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES App 20160089426 - HOERR; Ingmar ; et al.	2016-03-31
APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES App 20160089425 - HOERR; Ingmar ; et al.	2016-03-31
APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES App 20160089424 - HOERR; Ingmar ; et al.	2016-03-31
APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES App 20160082092 - HOERR; Ingmar ; et al.	2016-03-24
Nucleic acids comprising formula (N.sub.uG.sub.lX.sub.mG.sub.nN.sub.v).sub.a and derivatives thereof as immunostimulating agent/adjuvant Grant 9,226,959 - Kramps , et al. January 5, 2	2016-01-05
Application of mRNA for use as a therapeutic against tumour diseases Grant 9,155,788 - Hoerr , et al. October 13, 2	2015-10-13
PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS App 20150104476 - VON DER MULBE; Florian ; et al.	2015-04-16
Application Of Mrna For Use As A Therapeutic Against Tumour Diseases App 20150030633 - HOERR; Ingmar ; et al.	2015-01-29
Immunostimulation By Chemically Modified Rna App 20130273001 - HOERR; Ingmar ; et al.	2013-10-17
COMPOSITION FOR TREATING PROSTATE CANCER (PCa) App 20130251742 - Probst; Jochen ; et al.	2013-09-26
Composition For Treating Lung Cancer, Particularly Of Non-small Lung Cancers (nsclc) App 20130202645 - Barner; Marijke ; et al.	2013-08-08
Rna-coded Antibody App 20130195867 - HOERR; Ingmar ; et al.	2013-08-01
Nucleic Acid of Formula (I): GlXmGn, or (II): ClXmCn, in Particular as an Immune-Stimulating Agent/Adjuvant App 20130121988 - Hoerr; Ingmar ; et al.	2013-05-16
Combination Therapy For Immunostimulation App 20120213818 - Hoerr; Ingmar ; et al.	2012-08-23
Application of mRNA for use as a therapeutic agent for tumorous diseases Grant 8,217,016 - Hoerr , et al. July 10, 2	2012-07-10
Nucleic Acids Comprising formula (NuGlXmGnNv)a and Derivatives Thereof as Immunostimulating Agent/Adjuvant App 20120021043 - Kramps; Thomas ; et al.	2012-01-26
Transfection Of Blood Cells With Mrna For Immune Stimulation And Gene Therapy App 20120009221 - HOERR; INGMAR ; et al.	2012-01-12
Application Of Mrna For Use As A Therapeutic Against Tumour Diseases App 20110311472 - HOERR; Ingmar ; et al.	2011-12-22
PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS App 20110269950 - Von Der Mulbe; Florian ; et al.	2011-11-03
Pharmaceutical Composition Containing A Stabilised Mrna Optimised For Translation In Its Coding Regions App 20110077287 - VON DER MULBE; FLORIAN ; et al.	2011-03-31
Immunostimulation By Chemically Modified Rna App 20100303851 - HOERR; INGMAR ; et al.	2010-12-02
COMPOSITION FOR TREATING PROSTATE CANCER (PCa) App 20100305196 - Probst; Jochen ; et al.	2010-12-02
Composition For Treating Lung Cancer, Particularly Of Non-small Lung Cancers (nsclc) App 20100291156 - Barner; Marijke ; et al.	2010-11-18
PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS App 20100239608 - VON DER MULBE; FLORIAN ; et al.	2010-09-23
Rna-coded Antibody App 20100189729 - Hoerr; Ingmar ; et al.	2010-07-29
Base-modified Rna For Increasing The Expression Of A Protein App 20100047261 - Hoerr; Ingmar ; et al.	2010-02-25
Nucleic Acid of Formula (I): GIXmGn, or (II): CIXmCn, in Particular as an Immune-Stimulating Agent/Adjuvant App 20090324584 - Hoerr; Ingmar ; et al.	2009-12-31
Injection Solution for Rna App 20080267873 - Hoerr; Ingmar ; et al.	2008-10-30
Mrna Mixture For Vaccinating Against Tumoral Diseases App 20080171711 - Hoerr; Ingmar ; et al.	2008-07-17
Combination Therapy for Immunostimulation App 20080025944 - Hoerr; Ingmar ; et al.	2008-01-31
Adjuvant In The Form Of A Lipid-modified Nucleic Acid App 20070280929 - Hoerr; Ingmar ; et al.	2007-12-06
Transfection of blood cells with mRNA for immune stimulation and gene therapy App 20060188490 - Hoerr; Ingmar ; et al.	2006-08-24
Immunostimulation by chemically modified RNA App 20050250723 - Hoerr, Ingmar ; et al.	2005-11-10
Application of mRNA for use as a therapeutic against tumour diseases App 20050059624 - Hoerr, Ingmar ; et al.	2005-03-17
Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions App 20050032730 - Von Der Mulbe, Florian ; et al.	2005-02-10

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.